The seven-year amount needs context
A multistate Sandoz and Fougera generic-drug agreement announced October 1 adds a major proposed recovery in ongoing price-fixing litigation. New York's attorney general describes $320,560,180 paid with interest over seven years, totaling $400 million. The interest-inclusive figure should not be reported as money already distributed to consumers.
Pennsylvania's October 2 announcement says the states are seeking court approval and that nearly $15 million could come to Pennsylvania. The new deal is distinct from the earlier approximately $96.5 million generic-drug settlement pool. A new headline total is not a fixed household award or proof of an immediate payment date.
Existing claims and the new deal differ
The states direct potentially eligible consumers to the existing generic-drug settlement administrator, with covered purchase lists and historical purchase periods. A prescription being generic is not sufficient: the particular drug, purchase date, state and claims instructions still matter. Preserve pharmacy and payment records if available.
The announced agreement also includes cooperation and antitrust-compliance commitments. Follow the administrator for claim and allocation updates rather than assuming a current claim automatically produces a share of every later agreement. A proposed recovery paid over years and an open earlier claim window are related but different stages of the litigation.